Company news
Ironwood Pharmaceuticals, Inc. news in 2026
Ironwood Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.
Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)
November 5, 2026
Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance
November 5, 2026
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
October 28, 2026
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
October 16, 2026
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 3, 2026
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
August 6, 2026
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
July 30, 2026
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
July 14, 2026
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
May 27, 2026
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth, Maintains Full-Year 2026 Financial Guidance
May 8, 2026
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
May 7, 2026
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
May 4, 2026
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
April 30, 2026
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
April 23, 2026
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
February 25, 2026
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
February 18, 2026
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
January 1, 2026
Calls in 2026
- Ironwood Pharmaceuticals (NASDAQ:IRWD) Q3 2026 Earnings Call
Nov 5, 2026
Transcript - Ironwood Pharmaceuticals (NASDAQ:IRWD) Q2 2026 Earnings Call
Aug 6, 2026
Transcript - Ironwood Pharmaceuticals (NASDAQ:IRWD) Q1 2026 Earnings Call
May 7, 2026
Transcript - Ironwood Pharmaceuticals (NASDAQ:IRWD) Q4 2025 Earnings Call
Feb 25, 2026
Transcript
Decks in 2026
- Q3 2026 Earnings Presentation
Earnings · 19 slides · Nov 5, 2026
- Q2 2026 Earnings Presentation
Earnings · 19 slides · Aug 6, 2026
- Q1 2026 Earnings Presentation
Earnings · 18 slides · May 7, 2026
- Q4 2025 Earnings Presentation
Earnings · 22 slides · Feb 25, 2026